GLP-1 access guide
Is compounded semaglutide the same as Wegovy or Ozempic?
No. A compounded preparation described as semaglutide is not the same FDA-approved finished product as Wegovy or Ozempic. The exact ingredients, formulation, packaging and source can differ, and the preparation has not inherited either brand’s approval or an approved generic’s equivalence determination. Ask the clinician and pharmacy to identify the actual product; a shared ingredient heading or lower price does not establish interchangeability. [1][2][3]
A molecule name and a product name answer different questions
Semaglutide is the ingredient name associated with Wegovy and Ozempic branded products. The brand identifies a particular approved finished drug rather than every preparation described under that ingredient heading. FDA’s approval process concerns the specific product and supported labeling. A compounded program is a separate preparation and service arrangement, even when its marketing compares the price with those brands. [4][5][6]
This distinction avoids two errors: treating an ingredient name as proof that all products are identical, and assuming that every differently branded offer contains a different ingredient. The directory keeps ingredient, brand, formulation and compounded status separate. It does not authenticate the chemical contents of an individual compounded product or determine that it can substitute for a patient’s branded prescription. [1][2]
The compounded preparation can have a different description
FDA describes differences among compounded semaglutide preparations, including packaging and added ingredients. A semaglutide-plus-B12 label supplies more information than semaglutide alone; an injection label supplies different information from a sublingual-drops label. Keep those descriptions with the quote rather than stripping them away because the broad ingredient name matches. The full preparation is what the prescribing team and pharmacy must identify. [3][7]
FDA also identifies semaglutide sodium and acetate as different active ingredients from those in the approved drugs. A general semaglutide label cannot settle that distinction. Ask the pharmacist to resolve unclear ingredient information, and do not infer contents from a company’s familiar brand comparison. The directory’s recorded label is evidence of a published claim, not chemical authentication. [8]
FDA approval does not transfer from the brand
Approval of Wegovy or Ozempic belongs to the manufacturer’s approved finished product and labeling. Compounded drugs have not undergone FDA premarket approval, regardless of whether a pharmacy is licensed or registered in another regulatory category. The same ingredient heading does not extend a branded product’s approval to a pharmacy preparation. Our approval-status guide explains why these records are separate. [6][1]
An FDA-approved generic is another category with its own approval requirements, including relevant dosage form and bioequivalence requirements. A compounded prescription is not an approved generic merely because it is cheaper or presented as an alternative. The distinction here is regulatory identification, not a prediction of personal treatment response or a statement that any two preparations have been clinically compared. [2]
The legal framework differs from brand approval
FDA’s current reminder describes patient-specific 503A compounding, copy restrictions and separate 503B bulk-substance conditions after shortage resolution. The fact that an approved brand exists is relevant to that framework, but it does not decide whether an individual compounded prescription satisfies every condition. The actual prescriber and compounder must address the proposed preparation under the applicable rules. [9][10]
Adding an ingredient does not automatically settle the essentially-copy issue. FDA’s policy reminder includes a semaglutide-and-B12 example and discusses documented significant differences for an identified patient. A provider’s use of personalized in marketing should not be converted into a directory certification of compliance. Our legal guide explains the conditional framework without making an individual legal determination. [9]
A price comparison must preserve these distinctions
Our compounded-semaglutide price comparison groups documented offers within the compounded injection category and retains their formulation, dose-coverage evidence and billing unit. It is a financial comparison of recorded offers, not a therapeutic-equivalence finding. A branded pharmacy package and a bundled telehealth compound plan can also differ in their included services, payment terms and unresolved fees. The smallest headline number does not remove those differences. [7][11][12][13]
Brand savings programs apply to their named products and eligibility rules. A NovoCare Wegovy or Ozempic quote is not a compounded-semaglutide price, and a telehealth membership fee is not the manufacturer pharmacy amount. The brand-specific cost guides show those categories separately. Readers should identify the actual prescription before choosing which price evidence is relevant. [4][5]
What to ask the care team
Ask which finished preparation is proposed, which entity dispenses it and how the organization describes its approval and compounding status. If a pharmacy changes, obtain the new product identification rather than assuming the previous label applies. FDA’s online-pharmacy information provides basic prescription and licensing checks, while the care team and pharmacist handle the individual clinical and product questions. [14][1]
This guide does not instruct a reader to replace a branded medicine, change a preparation or translate one product’s instructions into another’s. It explains why the names alone do not establish the same finished product. A clear answer from the clinician and pharmacy should identify the preparation rather than relying only on an advertisement saying it is like a familiar brand. [1][6]
A hypothetical matched-name comparison
Suppose one quote identifies Wegovy in its manufacturer package and another identifies compounded semaglutide plus an additional ingredient from a named pharmacy. Both may be organized under semaglutide for research, but the descriptions have not established the same finished product. Approval, exact composition, packaging and included services still need their own identification. A price table should preserve that distinction instead of presenting the shared heading as proof of substitution. [1][3][2]
Now suppose a compounded offer uses only the short semaglutide label. Removing a disclosed additive from the description is not evidence that the formula equals the approved brand; it may simply mean the advertisement has not established the full composition. Ask the pharmacist to identify the preparation rather than turning missing information into a conclusion of sameness. [1][14]
Additional reading from a provider
These pages describe a provider’s perspective or its own service. The official documents cited in this guide establish regulatory, approval and program facts.
- Gentle Health: Ozempic, Wegovy, Zepbound and Mounjaro overview (provider-authored)
Gentle’s four-brand overview places its compounded services in a separate category; the approved-product labels above supply our identity facts.
Checked
Sources
Sources are checked on the dates shown. Official documents establish product and program rules; provider sources describe their own offers and the additional reading identified above. Provider catalog examples retain their original price-check dates; this article’s preparation date does not refresh them.
- FDA: compounding questions and answers — checked .
- FDA: generic drug facts and approval requirements — checked .
- FDA: compounded semaglutide product differences and added ingredients — checked .
- NovoCare: Wegovy cost and savings — checked .
- NovoCare Pharmacy: Ozempic self-pay terms — checked .
- FDA: development and approval process for drugs — checked .
- Gentle Health: advertised formulations and clinical process — checked .
- FDA: unapproved GLP-1 drugs — checked .
- FDA: compounding policies as GLP-1 supply stabilizes — checked .
- FDA: provisions applying to 503A and 503B compounding — checked .
- Cora Health: recorded medication programs — checked .
- Trimi: compounded semaglutide and tirzepatide programs — checked .
- FTC: trials, automatic renewals and subscriptions — checked .
- FDA BeSafeRx: online pharmacy questions — checked .
- Gentle Health: Ozempic, Wegovy, Zepbound and Mounjaro overview (provider-authored) — checked .